Lyka Labs Limited has informed the Exchange about change in Management
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 3.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lyka Labs announced its Q1 FY26 (quarter ended June 30, 2025) results along with key management changes. Standalone revenue from operations came in at Rs. 2,917.64 lakhs (vs Rs. 3,010.47 lakhs in Q1 FY25), while net profit fell sharply to Rs. 81.42 lakhs from Rs. 174.96 lakhs a year ago, with EPS dropping to Rs. 0.22 from Rs. 0.49. On a consolidated basis, revenue was Rs. 3,302.54 lakhs and net profit Rs. 99.62 lakhs (down from Rs. 128.95 lakhs). The Board accepted the resignation of Mr. Shekhar R Singh as Company Secretary, Compliance Officer and Nodal Officer, effective close of business on July 30, 2025, citing his pursuit of an external career opportunity; he will stay on through the upcoming 46th AGM to ensure a smooth handover. Sudit K Parekh & Co. LLP was appointed as the new Internal Auditor for FY 2025-26. The subsidiary Lyka BDR International Ltd also wrote off a Rs. 68.48 lakh claim related to an earlier product quality issue.
Profitability has weakened significantly year-on-year in Q1 despite stable topline, which could weigh on short-term sentiment. The Company Secretary (a KMP) exit is a routine mid-level change with a planned handover, but investors should watch for a timely replacement before the AGM.